Latest filing published 02 Feb 2026 for Cibus, Inc., €417k.
Filing timeline
BuySaleInsider track record
Closed purchases
Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- -74.6%Entry US$15.30 · Close at T+365 US$3.89
- -14.4%Entry US$50.25 · Close at T+365 US$43.03
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Rory B. Riggs: trading record in brief
Rory B. Riggs is a declared insider at 4 companies; the most frequent names are Royalty Pharma plc, Intra-Cellular Therapies, Inc. and Cibus, Inc. In total, 177 filings cover trades dated from 12 December 2002 to 29 January 2026.
In open-market terms, that means 7 purchases worth €6.3M on one side and 61 sales worth €224.1M on the other. Taken together, the sales exceed the purchases by €217.8M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Other entries cover 63 share grants and 6 option exercises.
In size, the median ticket on the buying side is €221k. Of 3 purchases, 2 formed part of a group of insiders buying within 30 days of each other. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.
Most recently, on 2 February 2026, the filings show a share grant worth €417k in Cibus, Inc. The latest purchase dates back some time: it was published 1,060 days ago, on 14 December 2023. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Rory B. Riggs
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 333,333 shares@ US$1.503.8% of flowClass A Common StockSEC:0001193125-26-034092:0
- 50,000 shares@ US$0.010.0% of flowClass A Common StockSEC:0000950170-25-084928:1
- 4,000,000 shares0.0% of flowClass A Common StockSEC:0000950170-25-084928:0
- 5,714,286 shares@ US$1.7579.5% of flowClass A Common StockSEC:0000950170-25-084320:0
- 131,512 shares@ US$132.0090.4% of flowCommon StockSEC:0000950170-25-049648:0
- 1,388,084 sharesClass A Common StockSEC:0001615594-25-000004:1
- 1,388,084 sharesClass B Common StockSEC:0001615594-25-000004:0
- 215 shares@ US$83.520.1% of flowCommon StockSEC:0000950170-25-001440:0
- 14,189 sharesCommon StockSEC:0000950170-24-114785:0
- 246 shares@ US$73.170.1% of flowCommon StockSEC:0000950170-24-111766:0
- 250,000 shares@ US$4.008.2% of flowClass A Common StockSEC:0000950170-24-108504:0
- 262 shares@ US$68.490.1% of flowCommon StockSEC:0000950170-24-080986:0
- 20,000 shares@ US$16.861.1% of flowCommon StockSEC:0000950170-24-077468:1
- 4,462 shares@ US$75.571.1% of flowCommon StockSEC:0000950170-24-077468:2
- 1,567 sharesCommon StockSEC:0000950170-24-077468:0
- 98,040 shares@ US$10.208.5% of flowClass A Common StockSEC:0000950170-24-073319:0
- 260 shares@ US$69.200.1% of flowCommon StockSEC:0000950170-24-040165:0
- 20,000 shares@ US$18.561.9% of flowCommon StockSEC:0000950170-24-035358:0
- 300,000 shares0Class A Ordinary SharesSEC:0001802768-24-000014:0
- 199,098 shares@ US$27.792.7% of flowClass A Ordinary SharesSEC:0001802768-24-000002:1
- 35,702 shares@ US$27.550.5% of flowClass A Ordinary SharesSEC:0001802768-24-000002:2
- 235,200 shares@ US$28.51656.7% of flowClass A Ordinary SharesSEC:0001802768-24-000002:0
- 1,500,000 shares0Class B Common StockSEC:0000899243-24-000057:1
- 1,500,000 shares0Class A Common StockSEC:0000899243-24-000057:2
- 251 shares@ US$71.620.1% of flowCommon StockSEC:0000950170-24-001305:0
25 of 175 declarations
